FITC标记的肿瘤异常甲基化蛋白1抗体
产品名称： FITC标记的肿瘤异常甲基化蛋白1抗体
英文名称： Anti-HIC1/FITC
产品编号： HZ-15485R-FITC
产品价格： null
产品产地： 中国/上海
品牌商标： HZbscience
更新时间： 2023-08-17T10:24:20
使用范围： ICC=1:50-200 IF=1:50-200
上海沪震实业有限公司
- 联系人 : 鲍丽雯
- 地址 : 上海市闵行区闵北路88弄1-30号第22幢AQ136室
- 邮编 : 200612
- 所在区域 : 上海
- 电话 : 139****0749 点击查看
- 传真 : 点击查看
- 邮箱 : www.shzbio.net
- 二维码 : 点击查看
Rabbit Anti-HIC1/FITC Conjugated antibody
FITC标记的肿瘤异常甲基化蛋白1抗体
| 英文名称 | Anti-HIC1/FITC |
| 中文名称 | FITC标记的肿瘤异常甲基化蛋白1抗体 |
| 别 名 | Hic 1; Hic-1; Hic1; HIC1_HUMAN; Hypermethylated in cancer 1; Hypermethylated in cancer 1 protein; ZBTB29; Zinc finger and BTB domain-containing protein 29; ZNF901. |
| 规格价格 | 100ul/2980元 购买 大包装/询价 |
| 说 明 书 | 100ul |
| 研究领域 | 染色质和核信号 表观遗传学 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, |
| 产品应用 | ICC=1:50-200 IF=1:50-200 not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 76kDa |
| 性 状 | Lyophilized or Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human HIC1 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 储 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 产品介绍 | background: Hypermethylated in cancer (HIC-1) was originally identified as a target of p53-induced gene expression. HIC-1 is deleted in the genetic disorder Miller-Dieker syndrome (MDS), and the expression of HIC-1 is also frequently suppressed in leukemia and various cancers due to the hypermethylation of specific DNA regions and the resulting transcriptional silencing. These and other studies indicate that HIC-1 acts as a putative tumor suppressor protein that mediates transcriptional repression. HIC-1 is ubiquitously expressed in adult tissues and its structure is defined by five zinc fingers and an N-terminal broad complex POZ (or BTB) domain. In several BTB/POZ containing proteins, including BCL-6 and the promyelocytic leukemia zinc-finger (PLZF) oncoprotein, this domain interacts with the SMRT/N-CoR-mSin3A HDAC complex and is directly involved in repressing and silencing gene transcription. When this domain is deleted, as with the oncogenic PLZF-RAR chimera of promyelocytic leukemias, this transcriptional repression is attenuated. Conversely, HIC-1 does not interact with components of the HDAC complex, suggesting that HIC-1-induced transcriptional repression is unassociated with the POZ/BTB domain. Function: Transcriptional repressor. Recognizes and binds to the consensus sequence '5-[CG]NG[CG]GGGCA[CA]CC-3'. May act as a tumor suppressor. May be involved in development of head, face, limbs and ventral body wall. Involved in down-regulation of SIRT1 and thereby is involved in regulation of p53/TP53-dependent apoptotic DNA-damage responses. The specific target gene promoter association seems to be depend on corepressors, such as CTBP1 or CTBP2 and MTA1. The regulation of SIRT1 transcription in response to nutrient deprivation seems to involve CTBP1. In cooperation with MTA1 (indicative for an association with the NuRD complex) represses transcription from CCND1/cyclin-D1 and CDKN1C/p57Kip2 specifically in quiescent cells. Involved in regulation of the Wnt signaling pathway probably by association with TCF7L2 and preventing TCF7L2 and CTNNB1 association with promoters of TCF-responsive genes. Seems to repress transcription from E2F1 and ATOH1 which involves ARID1A, indicative for the participation of a distinct SWI/SNF-type chromatin-remodeling complex. Probably represses transcription from CXCR7, FGFBP1 and EFNA1. Subunit: Self-associates. Interacts with HIC2. Interacts with CTBP1 and CTBP2. Interacts with TCF7L2 and ARID1A. Interacts with MTA1 and MBD3; indicative for an association with the NuRD complex. Subcellular Location: Nucleus. Tissue Specificity: Ubiquitously expressed with highest levels found in lung, colon, prostate, thymus, testis and ovary. Expression is absent or decreased in many tumor cells. Post-translational modifications: Acetylated on several residues, including Lys-333. Lys-333 is deacetylated by SIRT1. Sumoylated on Lys-333 by a PIAS family member, which enhances interaction with MTA1, positively regulates transcriptional repression activity and is enhanced by HDAC4. Similarity: Belongs to the krueppel C2H2-type zinc-finger protein family. Hic subfamily. Contains 1 BTB (POZ) domain. Contains 5 C2H2-type zinc fingers. Database links: Entrez Gene: 3090 Human Omim: 603825 Human SwissProt: Q14526 Human Unigene: 695682 Human Unigene: 72956 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications |
癌症中的高甲基化（HIC-1）最初被鉴定为p53诱导的基因表达的靶点。HIC-1在遗传性疾病Miller-Dieker综合征(MDS)中缺失，并且HIC-1在白血病和各种癌症中由于特定DNA区域的高甲基化以及由此导致的转录沉默也经常被抑制。这些和其他研究表明，HIC-1作为一个假定的肿瘤抑制蛋白，介导转录抑制。HIC-1在成体组织中普遍表达，其结构由五个锌指和一个N端宽的复合体POZ（或BTB）结构域决定。在包含BCL-6和早幼粒细胞白血病锌指(PLZF)癌蛋白的一些BTB/POZ中，该结构域与SMRT/N-CoR-mSin3A HDAC复合物相互作用，并直接参与抑制和沉默基因转录。当这个结构域被删除时，与早幼粒细胞白血病的致癌PLZF-RAR嵌合体一样，这种转录抑制被减弱。相反，HIC-1不与HDAC复合物的组分相互作用，提示HIC-1诱导的转录抑制与POZ/BTB结构域不相关。